BBIO BridgeBio Pharma Inc

Price (delayed)

$14.32

Market cap

$2.17B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.26

Enterprise value

$3.48B

BridgeBio Pharma Inc. is a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. BridgeBio was founded in ...

Highlights
BBIO's EPS is up by 16% year-on-year and by 3.3% since the previous quarter
BBIO's net income is up by 14% year-on-year
BridgeBio Pharma's revenue has decreased by 12% from the previous quarter but it has increased by 11% YoY
The gross profit has contracted by 12% from the previous quarter but it has grown by 11% YoY
BBIO's equity is down by 44% year-on-year and by 10% since the previous quarter
BridgeBio Pharma's quick ratio has decreased by 32% YoY and by 16% from the previous quarter

Key stats

What are the main financial stats of BBIO
Market
Shares outstanding
151.37M
Market cap
$2.17B
Enterprise value
$3.48B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
27.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
44.77
Earnings
Revenue
$77.65M
EBIT
-$400.75M
EBITDA
-$388.8M
Free cash flow
-$314.32M
Per share
EPS
-$3.26
Free cash flow per share
-$2.13
Book value per share
-$8.39
Revenue per share
$0.53
TBVPS
$4.03
Balance sheet
Total assets
$623.04M
Total liabilities
$1.87B
Debt
$1.72B
Equity
-$1.25B
Working capital
$427.43M
Liquidity
Debt to equity
-1.37
Current ratio
4.52
Quick ratio
4.34
Net debt/EBITDA
-3.37
Margins
EBITDA margin
-500.7%
Gross margin
95.6%
Net margin
-619.7%
Operating margin
-659.6%
Efficiency
Return on assets
-63.6%
Return on equity
N/A
Return on invested capital
-21.2%
Return on capital employed
-79.9%
Return on sales
-516.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BBIO stock price

How has the BridgeBio Pharma stock price performed over time
Intraday
-3.89%
1 week
2.29%
1 month
23.66%
1 year
38.22%
YTD
87.93%
QTD
87.93%

Financial performance

How have BridgeBio Pharma's revenue and profit performed over time
Revenue
$77.65M
Gross profit
$74.21M
Operating income
-$512.2M
Net income
-$481.18M
Gross margin
95.6%
Net margin
-619.7%
BBIO's net margin is up by 23% year-on-year but it is down by 12% since the previous quarter
BBIO's operating margin is up by 20% YoY but it is down by 7% QoQ
BBIO's net income is up by 14% year-on-year
BridgeBio Pharma's revenue has decreased by 12% from the previous quarter but it has increased by 11% YoY

Growth

What is BridgeBio Pharma's growth rate over time

Valuation

What is BridgeBio Pharma stock price valuation
P/E
N/A
P/B
N/A
P/S
27.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
44.77
BBIO's EPS is up by 16% year-on-year and by 3.3% since the previous quarter
BBIO's equity is down by 44% year-on-year and by 10% since the previous quarter
The stock's price to sales (P/S) is 63% more than its last 4 quarters average of 16.7
BridgeBio Pharma's revenue has decreased by 12% from the previous quarter but it has increased by 11% YoY

Efficiency

How efficient is BridgeBio Pharma business performance
BBIO's ROS is up by 30% year-on-year but it is down by 10% since the previous quarter
The ROIC has grown by 19% YoY
The ROA has contracted by 12% YoY and by 11% from the previous quarter

Dividends

What is BBIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BBIO.

Financial health

How did BridgeBio Pharma financials performed over time
BBIO's total assets is 67% smaller than its total liabilities
BBIO's total assets is down by 38% year-on-year and by 15% since the previous quarter
BridgeBio Pharma's quick ratio has decreased by 32% YoY and by 16% from the previous quarter
BBIO's equity is down by 44% year-on-year and by 10% since the previous quarter
BBIO's debt to equity is up by 31% year-on-year and by 9% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.